Log in

NASDAQ:ANABAnaptysBio Stock Price, Forecast & News

$22.54
-0.53 (-2.30 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$22.41
Now: $22.54
$23.71
50-Day Range
$18.53
MA: $20.12
$23.24
52-Week Range
$10.00
Now: $22.54
$56.72
Volume182,184 shs
Average Volume423,348 shs
Market Capitalization$614.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.93
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Read More
AnaptysBio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8 million
Book Value$14.93 per share

Profitability

Net Income$-97,340,000.00

Miscellaneous

Employees78
Market Cap$614.89 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

How has AnaptysBio's stock been impacted by COVID-19 (Coronavirus)?

AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANAB shares have increased by 48.0% and is now trading at $22.54. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AnaptysBio?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AnaptysBio.

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for AnaptysBio.

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) issued its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.33. The biotechnology company had revenue of $15 million for the quarter, compared to the consensus estimate of $10 million. View AnaptysBio's earnings history.

What price target have analysts set for ANAB?

8 equities research analysts have issued 12-month target prices for AnaptysBio's shares. Their forecasts range from $12.00 to $140.00. On average, they anticipate AnaptysBio's stock price to reach $36.00 in the next year. This suggests a possible upside of 59.7% from the stock's current price. View analysts' price targets for AnaptysBio.

Has AnaptysBio been receiving favorable news coverage?

News headlines about ANAB stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AnaptysBio earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about AnaptysBio.

Who are some of AnaptysBio's key competitors?

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Editas Medicine (EDIT), NVIDIA (NVDA), Amarin (AMRN), Alibaba Group (BABA), bluebird bio (BLUE), Baozun (BZUN), Canopy Growth (CGC) and Clovis Oncology (CLVS).

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 43)
  • Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)
  • Prof. Marco Londei, Chief Medical Officer (Age 62)
  • Mr. Eric J. Loumeau, Gen. Counsel (Age 56)
  • Dr. Hemant Kumar, Sr. VP of Manufacturing

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $22.54.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $614.89 million and generates $8 million in revenue each year. The biotechnology company earns $-97,340,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.

What is AnaptysBio's official website?

The official website for AnaptysBio is www.anaptysbio.com.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.